Engage for Psychotherapy

Phase-Based Progress Estimates

Effectiveness

Safety

University of Nevada, Las Vegas, NV

Psychotherapy+6 More

Engage - Behavioral

You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.

Eligibility

18+

All Sexes

What conditions do you have?

Select

Eligibility

18+

All Sexes

What conditions do you have?

Select

Study Summary

Although there are an increasing number of mental health treatment adaptations for older adults, there are still a number of factors to consider when making these adaptations. Cognitive decline is one such factor that places significant burden on older adults and can interfere with traditional mental health therapies. Engage is a behavioral treatment approach that has shown to be effective in treating late life depression. We are testing the feasibility of Engage as a treatment method for late life depression in older adults with cognitive decline. Our objective is to corroborate Engage as an alternative late life depression treatment method for a sub-population of older adults with cognitive decline. Cognitive decline poses a unique mental health treatment barrier that is often over looked in younger populations. With a relatively higher prevalence of cognitive decline in older adulthood, it is imperative that we find a feasible mental health treatment program that can be effective in the presence of cognitive decline.

Eligible Conditions

Psychotherapy
Depression in Old Age
Executive Dysfunction
Mild Cognitive Impairment (MCI)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Psychotherapy

L-Dopa

Interpersonal Psychotherapy for Depressed Adolescents

Aripiprazole Augmentation

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Assessed at Baseline, Week 6, Week 9, and Week 36 follow-up.

Week 36

Behavioral Activation for Depression Scale (BADS)

Hamilton Depression Rating Scale

Social Problem-Solving Inventory Revised-Short Form

World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)

Week 36

Hopkins Verbal Learning Memory Test-Revised

Iowa Gambling Task - 2nd Edition

Stroop Color-Word Interference Test

Trail Making Test A & B

Trial Safety

Safety Progress

1 of 3

Other trials for Psychotherapy

L-Dopa

Interpersonal Psychotherapy for Depressed Adolescents

Aripiprazole Augmentation

Trial Design

1 Treatment Group

Engage Treatment

1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Engage · No Placebo Group · N/A

Engage Treatment

Behavioral

Experimental Group · 1 Intervention: Engage · Intervention Types: Behavioral

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Engage

2019

N/A

~1350

Trial Logistics

Trial Timeline

Approximate Timeline

Screening: ~3 weeks

Treatment: Varies

Reporting: assessed at baseline, week 6, week 9, and week 36 follow-up.

Trial Background

Prof. Brenna Renn, Assistant Professor

Principal Investigator

University of Nevada, Las Vegas

Closest Location: University of Nevada · Las Vegas, NV

2004First Recorded Clinical Trial

1 TrialsResearching Psychotherapy

8 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

You must be 60 years of age or older.

You are located in Las Vegas or surrounding area.

You are able to travel to the UNLV campus by yourself or with a caregiver.

About The Reviewer

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References